001package org.hl7.fhir.dstu3.model.codesystems; 002 003 004 005 006/* 007 Copyright (c) 2011+, HL7, Inc. 008 All rights reserved. 009 010 Redistribution and use in source and binary forms, with or without modification, 011 are permitted provided that the following conditions are met: 012 013 * Redistributions of source code must retain the above copyright notice, this 014 list of conditions and the following disclaimer. 015 * Redistributions in binary form must reproduce the above copyright notice, 016 this list of conditions and the following disclaimer in the documentation 017 and/or other materials provided with the distribution. 018 * Neither the name of HL7 nor the names of its contributors may be used to 019 endorse or promote products derived from this software without specific 020 prior written permission. 021 022 THIS SOFTWARE IS PROVIDED BY THE COPYRIGHT HOLDERS AND CONTRIBUTORS "AS IS" AND 023 ANY EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, THE IMPLIED 024 WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE ARE DISCLAIMED. 025 IN NO EVENT SHALL THE COPYRIGHT HOLDER OR CONTRIBUTORS BE LIABLE FOR ANY DIRECT, 026 INDIRECT, INCIDENTAL, SPECIAL, EXEMPLARY, OR CONSEQUENTIAL DAMAGES (INCLUDING, BUT 027 NOT LIMITED TO, PROCUREMENT OF SUBSTITUTE GOODS OR SERVICES; LOSS OF USE, DATA, OR 028 PROFITS; OR BUSINESS INTERRUPTION) HOWEVER CAUSED AND ON ANY THEORY OF LIABILITY, 029 WHETHER IN CONTRACT, STRICT LIABILITY, OR TORT (INCLUDING NEGLIGENCE OR OTHERWISE) 030 ARISING IN ANY WAY OUT OF THE USE OF THIS SOFTWARE, EVEN IF ADVISED OF THE 031 POSSIBILITY OF SUCH DAMAGE. 032 033*/ 034 035// Generated on Sat, Mar 25, 2017 21:03-0400 for FHIR v3.0.0 036 037 038import org.hl7.fhir.exceptions.FHIRException; 039 040public enum V3ObservationInterpretation { 041 042 /** 043 * Codes that specify interpretation of genetic analysis, such as "positive", "negative", "carrier", "responsive", etc. 044 */ 045 _GENETICOBSERVATIONINTERPRETATION, 046 /** 047 * The patient is considered as carrier based on the testing results. A carrier is an individual who carries an altered form of a gene which can lead to having a child or offspring in future generations with a genetic disorder. 048 */ 049 CAR, 050 /** 051 * The patient is considered as carrier based on the testing results. A carrier is an individual who carries an altered form of a gene which can lead to having a child or offspring in future generations with a genetic disorder. 052 053 054 055 Deprecation Comment: 056 This code is currently the same string as the print name for this concept and is inconsistent with the conventions being used for the other codes in the coding system, as it is a full word with initial capitalization, rather than an all upper case mnemonic. The recommendation from OO is to deprecate the code "Carrier" and to add "CAR" as the new active code representation for this concept. 057 */ 058 CARRIER, 059 /** 060 * Interpretations of change of quantity and/or severity. At most one of B or W and one of U or D allowed. 061 */ 062 _OBSERVATIONINTERPRETATIONCHANGE, 063 /** 064 * The current result or observation value has improved compared to the previous result or observation value (the change is significant as defined in the respective test procedure). 065 066 [Note: This can be applied to quantitative or qualitative observations.] 067 */ 068 B, 069 /** 070 * The current result has decreased from the previous result for a quantitative observation (the change is significant as defined in the respective test procedure). 071 */ 072 D, 073 /** 074 * The current result has increased from the previous result for a quantitative observation (the change is significant as defined in the respective test procedure). 075 */ 076 U, 077 /** 078 * The current result or observation value has degraded compared to the previous result or observation value (the change is significant as defined in the respective test procedure). 079 080 [Note: This can be applied to quantitative or qualitative observations.] 081 */ 082 W, 083 /** 084 * Technical exceptions resulting in the inability to provide an interpretation. At most one allowed. Does not imply normality or severity. 085 */ 086 _OBSERVATIONINTERPRETATIONEXCEPTIONS, 087 /** 088 * The result is below the minimum detection limit (the test procedure or equipment is the limiting factor). 089 090 Synonyms: Below analytical limit, low off scale. 091 */ 092 LESS_THAN, 093 /** 094 * The result is above the maximum quantifiable limit (the test procedure or equipment is the limiting factor). 095 096 Synonyms: Above analytical limit, high off scale. 097 */ 098 GREATER_THAN, 099 /** 100 * A valid result cannot be obtained for the specified component / analyte due to the presence of anti-complementary substances in the sample. 101 102 103 104 Deprecation Comment: 105 This code is being deprecated to match the status in V2 Table 0078 "Interpretation Codes. 106 */ 107 AC, 108 /** 109 * There is insufficient evidence that the species in question is a good target for therapy with the drug. A categorical interpretation is not possible. 110 111 [Note: A MIC with "IE" and/or a comment may be reported (without an accompanying S, I or R-categorization).] 112 */ 113 IE, 114 /** 115 * A result cannot be considered valid for the specified component / analyte or organism due to failure in the quality control testing component. 116 117 118 119 Deprecation Comment: 120 This code is being deprecated to match the status in V2 Table 0078 "Interpretation Codes. 121 */ 122 QCF, 123 /** 124 * A valid result cannot be obtained for the specified organism or cell line due to the presence of cytotoxic substances in the sample or culture. 125 126 127 128 Deprecation Comment: 129 This code is being deprecated to match the status in V2 Table 0078 "Interpretation Codes. 130 */ 131 TOX, 132 /** 133 * Interpretation of normality or degree of abnormality (including critical or "alert" level). Concepts in this category are mutually exclusive, i.e., at most one is allowed. 134 */ 135 _OBSERVATIONINTERPRETATIONNORMALITY, 136 /** 137 * The result or observation value is outside the reference range or expected norm (as defined for the respective test procedure). 138 139 [Note: Typically applies to non-numeric results.] 140 */ 141 A, 142 /** 143 * The result or observation value is outside a reference range or expected norm at a level at which immediate action should be considered for patient safety (as defined for the respective test procedure). 144 145 [Note: Typically applies to non-numeric results. Analogous to critical/panic limits for numeric results.] 146 */ 147 AA, 148 /** 149 * The result for a quantitative observation is above a reference level at which immediate action should be considered for patient safety (as defined for the respective test procedure). 150 151 Synonym: Above upper panic limits. 152 */ 153 HH, 154 /** 155 * The result for a quantitative observation is below a reference level at which immediate action should be considered for patient safety (as defined for the respective test procedure). 156 157 Synonym: Below lower panic limits. 158 */ 159 LL, 160 /** 161 * The result for a quantitative observation is above the upper limit of the reference range (as defined for the respective test procedure). 162 163 Synonym: Above high normal 164 */ 165 H, 166 /** 167 * A test result that is significantly higher than the reference (normal) or therapeutic interval, but has not reached the critically high value and might need special attention, as defined by the laboratory or the clinician.[Note: This level is situated between 'H' and 'HH'.] 168 169 170 Deprecation Comment: The code 'H>' is being deprecated in order to align with the use of the code 'HU' for "Very high" in V2 Table 0078 "Interpretation Codes". 171 172 [Note: The use of code 'H>' is non-preferred, as this code is deprecated and on track to be retired; use code 'HU' instead. 173 */ 174 H_, 175 /** 176 * A test result that is significantly higher than the reference (normal) or therapeutic interval, but has not reached the critically high value and might need special attention, as defined by the laboratory or the clinician. 177 */ 178 HU, 179 /** 180 * The result for a quantitative observation is below the lower limit of the reference range (as defined for the respective test procedure). 181 182 Synonym: Below low normal 183 */ 184 L, 185 /** 186 * A test result that is significantly lower than the reference (normal) or therapeutic interval, but has not reached the critically low value and might need special attention, as defined by the laboratory or the clinician.[Note: This level is situated between 'L' and 'LL'.] 187 188 189 Deprecation Comment: The code 'L<' is being deprecated in order to align with the use of the code 'LU' for "Very low" in V2 Table 0078 "Interpretation Codes". 190 191 [Note: The use of code 'L<' is non-preferred, as this code is deprecated and on track to be retired; use code 'LU' instead. 192 */ 193 L_, 194 /** 195 * A test result that is significantly lower than the reference (normal) or therapeutic interval, but has not reached the critically low value and might need special attention, as defined by the laboratory or the clinician. 196 */ 197 LU, 198 /** 199 * The result or observation value is within the reference range or expected norm (as defined for the respective test procedure). 200 201 [Note: Applies to numeric or non-numeric results.] 202 */ 203 N, 204 /** 205 * Interpretations of anti-microbial susceptibility testing results (microbiology). At most one allowed. 206 */ 207 _OBSERVATIONINTERPRETATIONSUSCEPTIBILITY, 208 /** 209 * Bacterial strain inhibited in vitro by a concentration of an antimicrobial agent that is associated with uncertain therapeutic effect. Reference: CLSI (http://www.clsi.org/Content/NavigationMenu/Resources/HarmonizedTerminologyDatabase/Harmonized_Terminolo.htm) 210Projects: ISO 20776-1, ISO 20776-2 211 212 [Note 1: Bacterial strains are categorized as intermediate by applying the appropriate breakpoints in a defined phenotypic test system.] 213 214 [Note 2: This class of susceptibility implies that an infection due to the isolate can be appropriately treated in body sites where the drugs are physiologically concentrated or when a high dosage of drug can be used.] 215 216 [Note 3: This class also indicates a "buffer zone," to prevent small, uncontrolled, technical factors from causing major discrepancies in interpretations.] 217 218 [Note 4: These breakpoints can be altered due to changes in circumstances (e.g., changes in commonly used drug dosages, emergence of new resistance mechanisms).] 219 */ 220 I, 221 /** 222 * The patient is considered as carrier based on the testing results. A carrier is an individual who carries an altered form of a gene which can lead to having a child or offspring in future generations with a genetic disorder. 223 224 225 226 Deprecation Comment: 227 This antimicrobial susceptibility test interpretation concept is recommended by OO to be deprecated as it is no longer recommended for use in susceptibility testing by CLSI (reference CLSI document M100-S22; Vol. 32 No.3; CLSI Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Second Informational Supplement. Jan 2012). 228 */ 229 MS, 230 /** 231 * A category used for isolates for which only a susceptible interpretive criterion has been designated because of the absence or rare occurrence of resistant strains. Isolates that have MICs above or zone diameters below the value indicated for the susceptible breakpoint should be reported as non-susceptible. 232 233 NOTE 1: An isolate that is interpreted as non-susceptible does not necessarily mean that the isolate has a resistance mechanism. It is possible that isolates with MICs above the susceptible breakpoint that lack resistance mechanisms may be encountered within the wild-type distribution subsequent to the time the susceptible-only breakpoint is set. 234 235 NOTE 2: For strains yielding results in the "nonsusceptible" category, organism identification and antimicrobial susceptibility test results should be confirmed. 236 237 Synonym: decreased susceptibility. 238 */ 239 NS, 240 /** 241 * Bacterial strain inhibited in vitro by a concentration of an antimicrobial agent that is associated with a high likelihood of therapeutic failure. 242Reference: CLSI (http://www.clsi.org/Content/NavigationMenu/Resources/HarmonizedTerminologyDatabase/Harmonized_Terminolo.htm) 243Projects: ISO 20776-1, ISO 20776-2 244 245 [Note 1: Bacterial strains are categorized as resistant by applying the appropriate breakpoints in a defined phenotypic test system.] 246 247 [Note 2: This breakpoint can be altered due to changes in circumstances (e.g., changes in commonly used drug dosages, emergence of new resistance mechanisms).] 248 */ 249 R, 250 /** 251 * A category for isolates where the bacteria (e.g. enterococci) are not susceptible in vitro to a combination therapy (e.g., high-level aminoglycoside and cell wall active agent). This is predictive that this combination therapy will not be effective. 252 253 254 Usage Note: Since the use of penicillin or ampicillin alone often results in treatment failure of serious enterococcal or other bacterial infections, combination therapy is usually indicated to enhance bactericidal activity. The synergy between a cell wall active agent (such as penicillin, ampicillin, or vancomycin) and an aminoglycoside (such as gentamicin, kanamycin or streptomycin) is best predicted by screening for high-level bacterial resistance to the aminoglycoside. 255 256 257 Open Issue: The print name of the code is very general and the description is very specific to a pair of classes of agents, which may lead to confusion of these concepts in the future should other synergies be found. 258 */ 259 SYNR, 260 /** 261 * Bacterial strain inhibited by in vitro concentration of an antimicrobial agent that is associated with a high likelihood of therapeutic success. 262Reference: CLSI (http://www.clsi.org/Content/NavigationMenu/Resources/HarmonizedTerminologyDatabase/Harmonized_Terminolo.htm) 263Synonym (earlier term): Sensitive Projects: ISO 20776-1, ISO 20776-2 264 265 [Note 1: Bacterial strains are categorized as susceptible by applying the appropriate breakpoints in a defined phenotypic system.] 266 267 [Note 2: This breakpoint can be altered due to changes in circumstances (e.g., changes in commonly used drug dosages, emergence of new resistance mechanisms).] 268 */ 269 S, 270 /** 271 * A category that includes isolates with antimicrobial agent minimum inhibitory concentrations (MICs) that approach usually attainable blood and tissue levels and for which response rates may be lower than for susceptible isolates. 272 273 Reference: CLSI document M44-A2 2009 "Method for antifungal disk diffusion susceptibility testing of yeasts; approved guideline - second edition" - page 2. 274 */ 275 SDD, 276 /** 277 * A category for isolates where the bacteria (e.g. enterococci) are susceptible in vitro to a combination therapy (e.g., high-level aminoglycoside and cell wall active agent). This is predictive that this combination therapy will be effective. 278 279 280 Usage Note: Since the use of penicillin or ampicillin alone often results in treatment failure of serious enterococcal or other bacterial infections, combination therapy is usually indicated to enhance bactericidal activity. The synergy between a cell wall active agent (such as penicillin, ampicillin, or vancomycin) and an aminoglycoside (such as gentamicin, kanamycin or streptomycin) is best predicted by screening for high-level bacterial resistance to the aminoglycoside. 281 282 283 Open Issue: The print name of the code is very general and the description is very specific to a pair of classes of agents, which may lead to confusion of these concepts in the future should other synergies be found. 284 */ 285 SYNS, 286 /** 287 * The patient is considered as carrier based on the testing results. A carrier is an individual who carries an altered form of a gene which can lead to having a child or offspring in future generations with a genetic disorder. 288 289 290 291 Deprecation Comment: 292 This antimicrobial susceptibility test interpretation concept is recommended by OO to be deprecated as it is no longer recommended for use in susceptibility testing by CLSI (reference CLSI document M100-S22; Vol. 32 No.3; CLSI Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Second Informational Supplement. Jan 2012). 293 */ 294 VS, 295 /** 296 * The observation/test result is interpreted as being outside the inclusion range for a particular protocol within which the result is being reported. 297 298 299 Example: A positive result on a Hepatitis screening test. 300 Open Issue: EX, HX, LX: These three concepts do not seem to meet a clear need in the vocabulary, and their use in observation interpretation appears likely to be covered by other existing concepts (e.g., A, H, L). The only apparent significant difference is their reference to use in protocols for exclusion of study subjects. 301These concepts/codes were proposed by RCRIM for use in the CTLaboratory message. They were submitted and approved in the November 2005 Harmonization cycle in proposal "030103C_VOCAB_RCRIM_l_quade_RCRIM Obs Interp_20051028154455". However, this proposal was not fully implemented in the vocabulary. The proposal recommended creation of the x_ClinicalResearchExclusion domain in ObservationInterpretation with a value set including those three concepts/codes, but there is no subdomain of that name or equivalent with a binding to either of the value sets that contain these concepts/codes. 302Members of the OO WG have recently attempted to contact members of RCRIM regarding these concepts, both by email and at the recent WGM in Atlanta, without response. It is felt by OO that the best course of action to take at this time is to add this comprehensive Open Issue rather than deprecate these three concepts at this time, until further discussion is held. 303 */ 304 EX, 305 /** 306 * The observation/test result is interpreted as being outside the inclusion range for a particular protocol within which the result is being reported. 307 308 309 Example: A positive result on a Hepatitis screening test. 310 Open Issue: EX, HX, LX: These three concepts do not seem to meet a clear need in the vocabulary, and their use in observation interpretation appears likely to be covered by other existing concepts (e.g., A, H, L). The only apparent significant difference is their reference to use in protocols for exclusion of study subjects. These concepts/codes were proposed by RCRIM for use in the CTLaboratory message. They were submitted and approved in the November 2005 Harmonization cycle in proposal "030103C_VOCAB_RCRIM_l_quade_RCRIM Obs Interp_20051028154455". However, this proposal was not fully implemented in the vocabulary. The proposal recommended creation of the x_ClinicalResearchExclusion domain in ObservationInterpretation with a value set including those three concepts/codes, but there is no subdomain of that name or equivalent with a binding to either of the value sets that contain these concepts/codes. Members of the OO WG have recently attempted to contact members of RCRIM regarding these concepts, both by email and at the recent WGM in Atlanta, without response. It is felt by OO that the best course of action to take at this time is to add this comprehensive Open Issue rather than deprecate these three concepts at this time, until further discussion is held. 311 */ 312 HX, 313 /** 314 * The numeric observation/test result is interpreted as being below the low threshold value for a particular protocol within which the result is being reported. 315 316 Example: A Total White Blood Cell Count falling below a protocol-defined threshold value of 3000/mm^3 317 Open Issue: EX, HX, LX: These three concepts do not seem to meet a clear need in the vocabulary, and their use in observation interpretation appears likely to be covered by other existing concepts (e.g., A, H, L). The only apparent significant difference is their reference to use in protocols for exclusion of study subjects. These concepts/codes were proposed by RCRIM for use in the CTLaboratory message. They were submitted and approved in the November 2005 Harmonization cycle in proposal "030103C_VOCAB_RCRIM_l_quade_RCRIM Obs Interp_20051028154455". However, this proposal was not fully implemented in the vocabulary. The proposal recommended creation of the x_ClinicalResearchExclusion domain in ObservationInterpretation with a value set including those three concepts/codes, but there is no subdomain of that name or equivalent with a binding to either of the value sets that contain these concepts/codes. Members of the OO WG have recently attempted to contact members of RCRIM regarding these concepts, both by email and at the recent WGM in Atlanta, without response. It is felt by OO that the best course of action to take at this time is to add this comprehensive Open Issue rather than deprecate these three concepts at this time, until further discussion is held. 318 */ 319 LX, 320 /** 321 * Hold for Medical Review 322 323 324 Usage Note: This code is not intended for use in V3 artifacts. It is included in the code system to maintain alignment with the V2 Table 0078 "Interpretation Codes." 325 */ 326 HM, 327 /** 328 * Interpretations of the presence or absence of a component / analyte or organism in a test or of a sign in a clinical observation. In keeping with laboratory data processing practice, these concepts provide a categorical interpretation of the "meaning" of the quantitative value for the same observation. 329 */ 330 OBSERVATIONINTERPRETATIONDETECTION, 331 /** 332 * The specified component / analyte, organism or clinical sign could neither be declared positive / negative nor detected / not detected by the performed test or procedure. 333 334 335 Usage Note: For example, if the specimen was degraded, poorly processed, or was missing the required anatomic structures, then "indeterminate" (i.e. "cannot be determined") is the appropriate response, not "equivocal". 336 */ 337 IND, 338 /** 339 * The test or procedure was successfully performed, but the results are borderline and can neither be declared positive / negative nor detected / not detected according to the current established criteria. 340 */ 341 E, 342 /** 343 * An absence finding of the specified component / analyte, organism or clinical sign based on the established threshold of the performed test or procedure. 344 345 [Note: Negative does not necessarily imply the complete absence of the specified item.] 346 */ 347 NEG, 348 /** 349 * The presence of the specified component / analyte, organism or clinical sign could not be determined within the limit of detection of the performed test or procedure. 350 */ 351 ND, 352 /** 353 * A presence finding of the specified component / analyte, organism or clinical sign based on the established threshold of the performed test or procedure. 354 */ 355 POS, 356 /** 357 * The measurement of the specified component / analyte, organism or clinical sign above the limit of detection of the performed test or procedure. 358 */ 359 DET, 360 /** 361 * Interpretation of the observed result taking into account additional information (contraindicators) about the patient's situation. Concepts in this category are mutually exclusive, i.e., at most one is allowed. 362 */ 363 OBSERVATIONINTERPRETATIONEXPECTATION, 364 /** 365 * This result has been evaluated in light of known contraindicators. Once those contraindicators have been taken into account the result is determined to be "Expected" (e.g., presence of drugs in a patient that is taking prescription medication for pain management). 366 */ 367 EXP, 368 /** 369 * This result has been evaluated in light of known contraindicators. Once those contraindicators have been taken into account the result is determined to be "Unexpected" (e.g., presence of non-prescribed drugs in a patient that is taking prescription medication for pain management). 370 */ 371 UNE, 372 /** 373 * Interpretation qualifiers in separate OBX segments 374 375 376 Usage Note: This code is not intended for use in V3 artifacts. It is included in the code system to maintain alignment with the V2 Table 0078 "Interpretation Codes." 377 */ 378 OBX, 379 /** 380 * Interpretations of the presence and level of reactivity of the specified component / analyte with the reagent in the performed laboratory test. 381 */ 382 REACTIVITYOBSERVATIONINTERPRETATION, 383 /** 384 * An absence finding used to indicate that the specified component / analyte did not react measurably with the reagent. 385 */ 386 NR, 387 /** 388 * A presence finding used to indicate that the specified component / analyte reacted with the reagent above the reliably measurable limit of the performed test. 389 */ 390 RR, 391 /** 392 * A weighted presence finding used to indicate that the specified component / analyte reacted with the reagent, but below the reliably measurable limit of the performed test. 393 */ 394 WR, 395 /** 396 * added to help the parsers 397 */ 398 NULL; 399 public static V3ObservationInterpretation fromCode(String codeString) throws FHIRException { 400 if (codeString == null || "".equals(codeString)) 401 return null; 402 if ("_GeneticObservationInterpretation".equals(codeString)) 403 return _GENETICOBSERVATIONINTERPRETATION; 404 if ("CAR".equals(codeString)) 405 return CAR; 406 if ("Carrier".equals(codeString)) 407 return CARRIER; 408 if ("_ObservationInterpretationChange".equals(codeString)) 409 return _OBSERVATIONINTERPRETATIONCHANGE; 410 if ("B".equals(codeString)) 411 return B; 412 if ("D".equals(codeString)) 413 return D; 414 if ("U".equals(codeString)) 415 return U; 416 if ("W".equals(codeString)) 417 return W; 418 if ("_ObservationInterpretationExceptions".equals(codeString)) 419 return _OBSERVATIONINTERPRETATIONEXCEPTIONS; 420 if ("<".equals(codeString)) 421 return LESS_THAN; 422 if (">".equals(codeString)) 423 return GREATER_THAN; 424 if ("AC".equals(codeString)) 425 return AC; 426 if ("IE".equals(codeString)) 427 return IE; 428 if ("QCF".equals(codeString)) 429 return QCF; 430 if ("TOX".equals(codeString)) 431 return TOX; 432 if ("_ObservationInterpretationNormality".equals(codeString)) 433 return _OBSERVATIONINTERPRETATIONNORMALITY; 434 if ("A".equals(codeString)) 435 return A; 436 if ("AA".equals(codeString)) 437 return AA; 438 if ("HH".equals(codeString)) 439 return HH; 440 if ("LL".equals(codeString)) 441 return LL; 442 if ("H".equals(codeString)) 443 return H; 444 if ("H>".equals(codeString)) 445 return H_; 446 if ("HU".equals(codeString)) 447 return HU; 448 if ("L".equals(codeString)) 449 return L; 450 if ("L<".equals(codeString)) 451 return L_; 452 if ("LU".equals(codeString)) 453 return LU; 454 if ("N".equals(codeString)) 455 return N; 456 if ("_ObservationInterpretationSusceptibility".equals(codeString)) 457 return _OBSERVATIONINTERPRETATIONSUSCEPTIBILITY; 458 if ("I".equals(codeString)) 459 return I; 460 if ("MS".equals(codeString)) 461 return MS; 462 if ("NS".equals(codeString)) 463 return NS; 464 if ("R".equals(codeString)) 465 return R; 466 if ("SYN-R".equals(codeString)) 467 return SYNR; 468 if ("S".equals(codeString)) 469 return S; 470 if ("SDD".equals(codeString)) 471 return SDD; 472 if ("SYN-S".equals(codeString)) 473 return SYNS; 474 if ("VS".equals(codeString)) 475 return VS; 476 if ("EX".equals(codeString)) 477 return EX; 478 if ("HX".equals(codeString)) 479 return HX; 480 if ("LX".equals(codeString)) 481 return LX; 482 if ("HM".equals(codeString)) 483 return HM; 484 if ("ObservationInterpretationDetection".equals(codeString)) 485 return OBSERVATIONINTERPRETATIONDETECTION; 486 if ("IND".equals(codeString)) 487 return IND; 488 if ("E".equals(codeString)) 489 return E; 490 if ("NEG".equals(codeString)) 491 return NEG; 492 if ("ND".equals(codeString)) 493 return ND; 494 if ("POS".equals(codeString)) 495 return POS; 496 if ("DET".equals(codeString)) 497 return DET; 498 if ("ObservationInterpretationExpectation".equals(codeString)) 499 return OBSERVATIONINTERPRETATIONEXPECTATION; 500 if ("EXP".equals(codeString)) 501 return EXP; 502 if ("UNE".equals(codeString)) 503 return UNE; 504 if ("OBX".equals(codeString)) 505 return OBX; 506 if ("ReactivityObservationInterpretation".equals(codeString)) 507 return REACTIVITYOBSERVATIONINTERPRETATION; 508 if ("NR".equals(codeString)) 509 return NR; 510 if ("RR".equals(codeString)) 511 return RR; 512 if ("WR".equals(codeString)) 513 return WR; 514 throw new FHIRException("Unknown V3ObservationInterpretation code '"+codeString+"'"); 515 } 516 public String toCode() { 517 switch (this) { 518 case _GENETICOBSERVATIONINTERPRETATION: return "_GeneticObservationInterpretation"; 519 case CAR: return "CAR"; 520 case CARRIER: return "Carrier"; 521 case _OBSERVATIONINTERPRETATIONCHANGE: return "_ObservationInterpretationChange"; 522 case B: return "B"; 523 case D: return "D"; 524 case U: return "U"; 525 case W: return "W"; 526 case _OBSERVATIONINTERPRETATIONEXCEPTIONS: return "_ObservationInterpretationExceptions"; 527 case LESS_THAN: return "<"; 528 case GREATER_THAN: return ">"; 529 case AC: return "AC"; 530 case IE: return "IE"; 531 case QCF: return "QCF"; 532 case TOX: return "TOX"; 533 case _OBSERVATIONINTERPRETATIONNORMALITY: return "_ObservationInterpretationNormality"; 534 case A: return "A"; 535 case AA: return "AA"; 536 case HH: return "HH"; 537 case LL: return "LL"; 538 case H: return "H"; 539 case H_: return "H>"; 540 case HU: return "HU"; 541 case L: return "L"; 542 case L_: return "L<"; 543 case LU: return "LU"; 544 case N: return "N"; 545 case _OBSERVATIONINTERPRETATIONSUSCEPTIBILITY: return "_ObservationInterpretationSusceptibility"; 546 case I: return "I"; 547 case MS: return "MS"; 548 case NS: return "NS"; 549 case R: return "R"; 550 case SYNR: return "SYN-R"; 551 case S: return "S"; 552 case SDD: return "SDD"; 553 case SYNS: return "SYN-S"; 554 case VS: return "VS"; 555 case EX: return "EX"; 556 case HX: return "HX"; 557 case LX: return "LX"; 558 case HM: return "HM"; 559 case OBSERVATIONINTERPRETATIONDETECTION: return "ObservationInterpretationDetection"; 560 case IND: return "IND"; 561 case E: return "E"; 562 case NEG: return "NEG"; 563 case ND: return "ND"; 564 case POS: return "POS"; 565 case DET: return "DET"; 566 case OBSERVATIONINTERPRETATIONEXPECTATION: return "ObservationInterpretationExpectation"; 567 case EXP: return "EXP"; 568 case UNE: return "UNE"; 569 case OBX: return "OBX"; 570 case REACTIVITYOBSERVATIONINTERPRETATION: return "ReactivityObservationInterpretation"; 571 case NR: return "NR"; 572 case RR: return "RR"; 573 case WR: return "WR"; 574 case NULL: return null; 575 default: return "?"; 576 } 577 } 578 public String getSystem() { 579 return "http://hl7.org/fhir/v3/ObservationInterpretation"; 580 } 581 public String getDefinition() { 582 switch (this) { 583 case _GENETICOBSERVATIONINTERPRETATION: return "Codes that specify interpretation of genetic analysis, such as \"positive\", \"negative\", \"carrier\", \"responsive\", etc."; 584 case CAR: return "The patient is considered as carrier based on the testing results. A carrier is an individual who carries an altered form of a gene which can lead to having a child or offspring in future generations with a genetic disorder."; 585 case CARRIER: return "The patient is considered as carrier based on the testing results. A carrier is an individual who carries an altered form of a gene which can lead to having a child or offspring in future generations with a genetic disorder.\r\n\n \n \n Deprecation Comment: \n This code is currently the same string as the print name for this concept and is inconsistent with the conventions being used for the other codes in the coding system, as it is a full word with initial capitalization, rather than an all upper case mnemonic. The recommendation from OO is to deprecate the code \"Carrier\" and to add \"CAR\" as the new active code representation for this concept."; 586 case _OBSERVATIONINTERPRETATIONCHANGE: return "Interpretations of change of quantity and/or severity. At most one of B or W and one of U or D allowed."; 587 case B: return "The current result or observation value has improved compared to the previous result or observation value (the change is significant as defined in the respective test procedure).\r\n\n [Note: This can be applied to quantitative or qualitative observations.]"; 588 case D: return "The current result has decreased from the previous result for a quantitative observation (the change is significant as defined in the respective test procedure)."; 589 case U: return "The current result has increased from the previous result for a quantitative observation (the change is significant as defined in the respective test procedure)."; 590 case W: return "The current result or observation value has degraded compared to the previous result or observation value (the change is significant as defined in the respective test procedure).\r\n\n [Note: This can be applied to quantitative or qualitative observations.]"; 591 case _OBSERVATIONINTERPRETATIONEXCEPTIONS: return "Technical exceptions resulting in the inability to provide an interpretation. At most one allowed. Does not imply normality or severity."; 592 case LESS_THAN: return "The result is below the minimum detection limit (the test procedure or equipment is the limiting factor).\r\n\n Synonyms: Below analytical limit, low off scale."; 593 case GREATER_THAN: return "The result is above the maximum quantifiable limit (the test procedure or equipment is the limiting factor).\r\n\n Synonyms: Above analytical limit, high off scale."; 594 case AC: return "A valid result cannot be obtained for the specified component / analyte due to the presence of anti-complementary substances in the sample.\r\n\n \n \n Deprecation Comment: \n This code is being deprecated to match the status in V2 Table 0078 \"Interpretation Codes."; 595 case IE: return "There is insufficient evidence that the species in question is a good target for therapy with the drug. A categorical interpretation is not possible.\r\n\n [Note: A MIC with \"IE\" and/or a comment may be reported (without an accompanying S, I or R-categorization).]"; 596 case QCF: return "A result cannot be considered valid for the specified component / analyte or organism due to failure in the quality control testing component.\r\n\n \n \n Deprecation Comment: \n This code is being deprecated to match the status in V2 Table 0078 \"Interpretation Codes."; 597 case TOX: return "A valid result cannot be obtained for the specified organism or cell line due to the presence of cytotoxic substances in the sample or culture.\r\n\n \n \n Deprecation Comment: \n This code is being deprecated to match the status in V2 Table 0078 \"Interpretation Codes."; 598 case _OBSERVATIONINTERPRETATIONNORMALITY: return "Interpretation of normality or degree of abnormality (including critical or \"alert\" level). Concepts in this category are mutually exclusive, i.e., at most one is allowed."; 599 case A: return "The result or observation value is outside the reference range or expected norm (as defined for the respective test procedure).\r\n\n [Note: Typically applies to non-numeric results.]"; 600 case AA: return "The result or observation value is outside a reference range or expected norm at a level at which immediate action should be considered for patient safety (as defined for the respective test procedure).\r\n\n [Note: Typically applies to non-numeric results. Analogous to critical/panic limits for numeric results.]"; 601 case HH: return "The result for a quantitative observation is above a reference level at which immediate action should be considered for patient safety (as defined for the respective test procedure).\r\n\n Synonym: Above upper panic limits."; 602 case LL: return "The result for a quantitative observation is below a reference level at which immediate action should be considered for patient safety (as defined for the respective test procedure).\r\n\n Synonym: Below lower panic limits."; 603 case H: return "The result for a quantitative observation is above the upper limit of the reference range (as defined for the respective test procedure).\r\n\n Synonym: Above high normal"; 604 case H_: return "A test result that is significantly higher than the reference (normal) or therapeutic interval, but has not reached the critically high value and might need special attention, as defined by the laboratory or the clinician.[Note: This level is situated between 'H' and 'HH'.]\r\n\n \n Deprecation Comment: The code 'H>' is being deprecated in order to align with the use of the code 'HU' for \"Very high\" in V2 Table 0078 \"Interpretation Codes\".\r\n\n [Note: The use of code 'H>' is non-preferred, as this code is deprecated and on track to be retired; use code 'HU' instead."; 605 case HU: return "A test result that is significantly higher than the reference (normal) or therapeutic interval, but has not reached the critically high value and might need special attention, as defined by the laboratory or the clinician."; 606 case L: return "The result for a quantitative observation is below the lower limit of the reference range (as defined for the respective test procedure).\r\n\n Synonym: Below low normal"; 607 case L_: return "A test result that is significantly lower than the reference (normal) or therapeutic interval, but has not reached the critically low value and might need special attention, as defined by the laboratory or the clinician.[Note: This level is situated between 'L' and 'LL'.]\r\n\n \n Deprecation Comment: The code 'L<' is being deprecated in order to align with the use of the code 'LU' for \"Very low\" in V2 Table 0078 \"Interpretation Codes\".\r\n\n [Note: The use of code 'L<' is non-preferred, as this code is deprecated and on track to be retired; use code 'LU' instead."; 608 case LU: return "A test result that is significantly lower than the reference (normal) or therapeutic interval, but has not reached the critically low value and might need special attention, as defined by the laboratory or the clinician."; 609 case N: return "The result or observation value is within the reference range or expected norm (as defined for the respective test procedure).\r\n\n [Note: Applies to numeric or non-numeric results.]"; 610 case _OBSERVATIONINTERPRETATIONSUSCEPTIBILITY: return "Interpretations of anti-microbial susceptibility testing results (microbiology). At most one allowed."; 611 case I: return "Bacterial strain inhibited in vitro by a concentration of an antimicrobial agent that is associated with uncertain therapeutic effect. Reference: CLSI (http://www.clsi.org/Content/NavigationMenu/Resources/HarmonizedTerminologyDatabase/Harmonized_Terminolo.htm)\nProjects: ISO 20776-1, ISO 20776-2\r\n\n [Note 1: Bacterial strains are categorized as intermediate by applying the appropriate breakpoints in a defined phenotypic test system.]\r\n\n [Note 2: This class of susceptibility implies that an infection due to the isolate can be appropriately treated in body sites where the drugs are physiologically concentrated or when a high dosage of drug can be used.]\r\n\n [Note 3: This class also indicates a \"buffer zone,\" to prevent small, uncontrolled, technical factors from causing major discrepancies in interpretations.]\r\n\n [Note 4: These breakpoints can be altered due to changes in circumstances (e.g., changes in commonly used drug dosages, emergence of new resistance mechanisms).]"; 612 case MS: return "The patient is considered as carrier based on the testing results. A carrier is an individual who carries an altered form of a gene which can lead to having a child or offspring in future generations with a genetic disorder.\r\n\n \n \n Deprecation Comment: \n This antimicrobial susceptibility test interpretation concept is recommended by OO to be deprecated as it is no longer recommended for use in susceptibility testing by CLSI (reference CLSI document M100-S22; Vol. 32 No.3; CLSI Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Second Informational Supplement. Jan 2012)."; 613 case NS: return "A category used for isolates for which only a susceptible interpretive criterion has been designated because of the absence or rare occurrence of resistant strains. Isolates that have MICs above or zone diameters below the value indicated for the susceptible breakpoint should be reported as non-susceptible.\r\n\n NOTE 1: An isolate that is interpreted as non-susceptible does not necessarily mean that the isolate has a resistance mechanism. It is possible that isolates with MICs above the susceptible breakpoint that lack resistance mechanisms may be encountered within the wild-type distribution subsequent to the time the susceptible-only breakpoint is set. \r\n\n NOTE 2: For strains yielding results in the \"nonsusceptible\" category, organism identification and antimicrobial susceptibility test results should be confirmed.\r\n\n Synonym: decreased susceptibility."; 614 case R: return "Bacterial strain inhibited in vitro by a concentration of an antimicrobial agent that is associated with a high likelihood of therapeutic failure.\nReference: CLSI (http://www.clsi.org/Content/NavigationMenu/Resources/HarmonizedTerminologyDatabase/Harmonized_Terminolo.htm) \nProjects: ISO 20776-1, ISO 20776-2\r\n\n [Note 1: Bacterial strains are categorized as resistant by applying the appropriate breakpoints in a defined phenotypic test system.]\r\n\n [Note 2: This breakpoint can be altered due to changes in circumstances (e.g., changes in commonly used drug dosages, emergence of new resistance mechanisms).]"; 615 case SYNR: return "A category for isolates where the bacteria (e.g. enterococci) are not susceptible in vitro to a combination therapy (e.g., high-level aminoglycoside and cell wall active agent). This is predictive that this combination therapy will not be effective. \r\n\n \n Usage Note: Since the use of penicillin or ampicillin alone often results in treatment failure of serious enterococcal or other bacterial infections, combination therapy is usually indicated to enhance bactericidal activity. The synergy between a cell wall active agent (such as penicillin, ampicillin, or vancomycin) and an aminoglycoside (such as gentamicin, kanamycin or streptomycin) is best predicted by screening for high-level bacterial resistance to the aminoglycoside.\r\n\n \n Open Issue: The print name of the code is very general and the description is very specific to a pair of classes of agents, which may lead to confusion of these concepts in the future should other synergies be found."; 616 case S: return "Bacterial strain inhibited by in vitro concentration of an antimicrobial agent that is associated with a high likelihood of therapeutic success.\nReference: CLSI (http://www.clsi.org/Content/NavigationMenu/Resources/HarmonizedTerminologyDatabase/Harmonized_Terminolo.htm)\nSynonym (earlier term): Sensitive Projects: ISO 20776-1, ISO 20776-2\r\n\n [Note 1: Bacterial strains are categorized as susceptible by applying the appropriate breakpoints in a defined phenotypic system.]\r\n\n [Note 2: This breakpoint can be altered due to changes in circumstances (e.g., changes in commonly used drug dosages, emergence of new resistance mechanisms).]"; 617 case SDD: return "A category that includes isolates with antimicrobial agent minimum inhibitory concentrations (MICs) that approach usually attainable blood and tissue levels and for which response rates may be lower than for susceptible isolates.\r\n\n Reference: CLSI document M44-A2 2009 \"Method for antifungal disk diffusion susceptibility testing of yeasts; approved guideline - second edition\" - page 2."; 618 case SYNS: return "A category for isolates where the bacteria (e.g. enterococci) are susceptible in vitro to a combination therapy (e.g., high-level aminoglycoside and cell wall active agent). This is predictive that this combination therapy will be effective. \r\n\n \n Usage Note: Since the use of penicillin or ampicillin alone often results in treatment failure of serious enterococcal or other bacterial infections, combination therapy is usually indicated to enhance bactericidal activity. The synergy between a cell wall active agent (such as penicillin, ampicillin, or vancomycin) and an aminoglycoside (such as gentamicin, kanamycin or streptomycin) is best predicted by screening for high-level bacterial resistance to the aminoglycoside.\r\n\n \n Open Issue: The print name of the code is very general and the description is very specific to a pair of classes of agents, which may lead to confusion of these concepts in the future should other synergies be found."; 619 case VS: return "The patient is considered as carrier based on the testing results. A carrier is an individual who carries an altered form of a gene which can lead to having a child or offspring in future generations with a genetic disorder.\r\n\n \n \n Deprecation Comment: \n This antimicrobial susceptibility test interpretation concept is recommended by OO to be deprecated as it is no longer recommended for use in susceptibility testing by CLSI (reference CLSI document M100-S22; Vol. 32 No.3; CLSI Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Second Informational Supplement. Jan 2012)."; 620 case EX: return "The observation/test result is interpreted as being outside the inclusion range for a particular protocol within which the result is being reported.\n\r\n\n Example: A positive result on a Hepatitis screening test.\n Open Issue: EX, HX, LX: These three concepts do not seem to meet a clear need in the vocabulary, and their use in observation interpretation appears likely to be covered by other existing concepts (e.g., A, H, L). The only apparent significant difference is their reference to use in protocols for exclusion of study subjects.\nThese concepts/codes were proposed by RCRIM for use in the CTLaboratory message. They were submitted and approved in the November 2005 Harmonization cycle in proposal \"030103C_VOCAB_RCRIM_l_quade_RCRIM Obs Interp_20051028154455\". However, this proposal was not fully implemented in the vocabulary. The proposal recommended creation of the x_ClinicalResearchExclusion domain in ObservationInterpretation with a value set including those three concepts/codes, but there is no subdomain of that name or equivalent with a binding to either of the value sets that contain these concepts/codes.\nMembers of the OO WG have recently attempted to contact members of RCRIM regarding these concepts, both by email and at the recent WGM in Atlanta, without response. It is felt by OO that the best course of action to take at this time is to add this comprehensive Open Issue rather than deprecate these three concepts at this time, until further discussion is held."; 621 case HX: return "The observation/test result is interpreted as being outside the inclusion range for a particular protocol within which the result is being reported.\n\r\n\n Example: A positive result on a Hepatitis screening test.\n Open Issue: EX, HX, LX: These three concepts do not seem to meet a clear need in the vocabulary, and their use in observation interpretation appears likely to be covered by other existing concepts (e.g., A, H, L). The only apparent significant difference is their reference to use in protocols for exclusion of study subjects. These concepts/codes were proposed by RCRIM for use in the CTLaboratory message. They were submitted and approved in the November 2005 Harmonization cycle in proposal \"030103C_VOCAB_RCRIM_l_quade_RCRIM Obs Interp_20051028154455\". However, this proposal was not fully implemented in the vocabulary. The proposal recommended creation of the x_ClinicalResearchExclusion domain in ObservationInterpretation with a value set including those three concepts/codes, but there is no subdomain of that name or equivalent with a binding to either of the value sets that contain these concepts/codes. Members of the OO WG have recently attempted to contact members of RCRIM regarding these concepts, both by email and at the recent WGM in Atlanta, without response. It is felt by OO that the best course of action to take at this time is to add this comprehensive Open Issue rather than deprecate these three concepts at this time, until further discussion is held."; 622 case LX: return "The numeric observation/test result is interpreted as being below the low threshold value for a particular protocol within which the result is being reported.\r\n\n Example: A Total White Blood Cell Count falling below a protocol-defined threshold value of 3000/mm^3\n Open Issue: EX, HX, LX: These three concepts do not seem to meet a clear need in the vocabulary, and their use in observation interpretation appears likely to be covered by other existing concepts (e.g., A, H, L). The only apparent significant difference is their reference to use in protocols for exclusion of study subjects. These concepts/codes were proposed by RCRIM for use in the CTLaboratory message. They were submitted and approved in the November 2005 Harmonization cycle in proposal \"030103C_VOCAB_RCRIM_l_quade_RCRIM Obs Interp_20051028154455\". However, this proposal was not fully implemented in the vocabulary. The proposal recommended creation of the x_ClinicalResearchExclusion domain in ObservationInterpretation with a value set including those three concepts/codes, but there is no subdomain of that name or equivalent with a binding to either of the value sets that contain these concepts/codes. Members of the OO WG have recently attempted to contact members of RCRIM regarding these concepts, both by email and at the recent WGM in Atlanta, without response. It is felt by OO that the best course of action to take at this time is to add this comprehensive Open Issue rather than deprecate these three concepts at this time, until further discussion is held."; 623 case HM: return "Hold for Medical Review\r\n\n \n Usage Note: This code is not intended for use in V3 artifacts. It is included in the code system to maintain alignment with the V2 Table 0078 \"Interpretation Codes.\""; 624 case OBSERVATIONINTERPRETATIONDETECTION: return "Interpretations of the presence or absence of a component / analyte or organism in a test or of a sign in a clinical observation. In keeping with laboratory data processing practice, these concepts provide a categorical interpretation of the \"meaning\" of the quantitative value for the same observation."; 625 case IND: return "The specified component / analyte, organism or clinical sign could neither be declared positive / negative nor detected / not detected by the performed test or procedure.\r\n\n \n Usage Note: For example, if the specimen was degraded, poorly processed, or was missing the required anatomic structures, then \"indeterminate\" (i.e. \"cannot be determined\") is the appropriate response, not \"equivocal\"."; 626 case E: return "The test or procedure was successfully performed, but the results are borderline and can neither be declared positive / negative nor detected / not detected according to the current established criteria."; 627 case NEG: return "An absence finding of the specified component / analyte, organism or clinical sign based on the established threshold of the performed test or procedure.\r\n\n [Note: Negative does not necessarily imply the complete absence of the specified item.]"; 628 case ND: return "The presence of the specified component / analyte, organism or clinical sign could not be determined within the limit of detection of the performed test or procedure."; 629 case POS: return "A presence finding of the specified component / analyte, organism or clinical sign based on the established threshold of the performed test or procedure."; 630 case DET: return "The measurement of the specified component / analyte, organism or clinical sign above the limit of detection of the performed test or procedure."; 631 case OBSERVATIONINTERPRETATIONEXPECTATION: return "Interpretation of the observed result taking into account additional information (contraindicators) about the patient's situation. Concepts in this category are mutually exclusive, i.e., at most one is allowed."; 632 case EXP: return "This result has been evaluated in light of known contraindicators. Once those contraindicators have been taken into account the result is determined to be \"Expected\" (e.g., presence of drugs in a patient that is taking prescription medication for pain management)."; 633 case UNE: return "This result has been evaluated in light of known contraindicators. Once those contraindicators have been taken into account the result is determined to be \"Unexpected\" (e.g., presence of non-prescribed drugs in a patient that is taking prescription medication for pain management)."; 634 case OBX: return "Interpretation qualifiers in separate OBX segments\r\n\n \n Usage Note: This code is not intended for use in V3 artifacts. It is included in the code system to maintain alignment with the V2 Table 0078 \"Interpretation Codes.\""; 635 case REACTIVITYOBSERVATIONINTERPRETATION: return "Interpretations of the presence and level of reactivity of the specified component / analyte with the reagent in the performed laboratory test."; 636 case NR: return "An absence finding used to indicate that the specified component / analyte did not react measurably with the reagent."; 637 case RR: return "A presence finding used to indicate that the specified component / analyte reacted with the reagent above the reliably measurable limit of the performed test."; 638 case WR: return "A weighted presence finding used to indicate that the specified component / analyte reacted with the reagent, but below the reliably measurable limit of the performed test."; 639 case NULL: return null; 640 default: return "?"; 641 } 642 } 643 public String getDisplay() { 644 switch (this) { 645 case _GENETICOBSERVATIONINTERPRETATION: return "GeneticObservationInterpretation"; 646 case CAR: return "Carrier"; 647 case CARRIER: return "Carrier"; 648 case _OBSERVATIONINTERPRETATIONCHANGE: return "ObservationInterpretationChange"; 649 case B: return "Better"; 650 case D: return "Significant change down"; 651 case U: return "Significant change up"; 652 case W: return "Worse"; 653 case _OBSERVATIONINTERPRETATIONEXCEPTIONS: return "ObservationInterpretationExceptions"; 654 case LESS_THAN: return "Off scale low"; 655 case GREATER_THAN: return "Off scale high"; 656 case AC: return "Anti-complementary substances present"; 657 case IE: return "Insufficient evidence"; 658 case QCF: return "Quality control failure"; 659 case TOX: return "Cytotoxic substance present"; 660 case _OBSERVATIONINTERPRETATIONNORMALITY: return "ObservationInterpretationNormality"; 661 case A: return "Abnormal"; 662 case AA: return "Critical abnormal"; 663 case HH: return "Critical high"; 664 case LL: return "Critical low"; 665 case H: return "High"; 666 case H_: return "Significantly high"; 667 case HU: return "Significantly high"; 668 case L: return "Low"; 669 case L_: return "Significantly low"; 670 case LU: return "Significantly low"; 671 case N: return "Normal"; 672 case _OBSERVATIONINTERPRETATIONSUSCEPTIBILITY: return "ObservationInterpretationSusceptibility"; 673 case I: return "Intermediate"; 674 case MS: return "moderately susceptible"; 675 case NS: return "Non-susceptible"; 676 case R: return "Resistant"; 677 case SYNR: return "Synergy - resistant"; 678 case S: return "Susceptible"; 679 case SDD: return "Susceptible-dose dependent"; 680 case SYNS: return "Synergy - susceptible"; 681 case VS: return "very susceptible"; 682 case EX: return "outside threshold"; 683 case HX: return "above high threshold"; 684 case LX: return "below low threshold"; 685 case HM: return "Hold for Medical Review"; 686 case OBSERVATIONINTERPRETATIONDETECTION: return "ObservationInterpretationDetection"; 687 case IND: return "Indeterminate"; 688 case E: return "Equivocal"; 689 case NEG: return "Negative"; 690 case ND: return "Not detected"; 691 case POS: return "Positive"; 692 case DET: return "Detected"; 693 case OBSERVATIONINTERPRETATIONEXPECTATION: return "ObservationInterpretationExpectation"; 694 case EXP: return "Expected"; 695 case UNE: return "Unexpected"; 696 case OBX: return "Interpretation qualifiers in separate OBX segments"; 697 case REACTIVITYOBSERVATIONINTERPRETATION: return "ReactivityObservationInterpretation"; 698 case NR: return "Non-reactive"; 699 case RR: return "Reactive"; 700 case WR: return "Weakly reactive"; 701 case NULL: return null; 702 default: return "?"; 703 } 704 } 705 706 707}